extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 
 At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence' and requiring countries to 'consider local cost-effectiveness, budget impact, and ethical implications.' The conditional framing signals uncertainty about long-term outcomes and sustainability, which compounds the chronic-use economic challenge. WHO's emphasis that GLP-1s must be embedded in comprehensive infrastructure (not standalone treatment) increases the total system cost beyond drug acquisition.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
 
 The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO's three-pillar framework for GLP-1 obesity treatment explicitly positions medication as one component within a comprehensive approach requiring: (1) population-level policies creating healthier environments, (2) protection for high-risk individuals, and (3) person-centered care including healthy diets, physical activity, and professional support. The WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly confirming that pharmaceutical intervention alone cannot address health outcomes driven by behavioral and social factors.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,11 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
 EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
+
+
+## Key Facts
+- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025
+- WHO's framework has three pillars: population-level policies, high-risk protection, and person-centered care
+- WHO emphasized obesity is a societal challenge requiring multisectoral action
+- WHO acknowledged limited long-term evidence for GLP-1s
+- WHO required countries to consider local cost-effectiveness, budget impact, and ethical implications